We would like to cordially invite you to the First EASL Nonalcoholic Fatty Liver Disease (NAFLD) Summit: Target-oriented approach to Diagnosis and Pharmacotherapy of Nonalcoholic Steatohepatitis (NASH), a dialogue between Academia and Industry’ to be held from 9-11 November 2017 in Rome, Italy.
Help us to inform the liver community by downloading the poster, printing it and placing it on your institute's notice board:
NAFLD is the leading cause of chronic liver disease not only in Western countries but also among developing countries of the Far East, South Asia, the Middle East, and Latin America. In the US and Europe, nearly 40% of the population have NAFLD and approximately 20% of these individuals are likely to develop progressive liver disease (i.e. NASH) that lead to liver fibrosis and cirrhosis. Another emerging challenge is hepatocellular cancer which increasingly arises in precirrhotic stages. Although a significant number of new drugs are already in the development pipeline, none are as yet, approved by regulatory agencies. As such, the identification and development of new therapies is urgently needed.
This summit will cover both the basic and translational/clinical aspects of NAFLD, with a specific focus on novel drug target and prognostic signature development.
This conference will be a unique platform for networking and an opportunity to display your brand to a worldwide market. If you would like to become a sponsor of the first EASL NAFLD Summit contact us.
|download pdf file||download pdf file|
NAFLD pathogenesis, patient management, prognostic and therapeutic targets, non-invasive assessment of fibrosis, apoptosis, biomarkers, insulin resistance and signalling, hormonal and bile acids signalling, oxidative and mitochondrial stress, inflammation and immunity in NASH, carcinogenesis, gut microbiota.
Abstract Submission is open up to and including 08 September 2017
Pharmaceutical companies will have to comply with regulations applicable to Congresses in Italy. All activities that pharmaceutical companies plan to undertake that are considered an interaction with healthcare professionals will have to be declared and approved by the Italian Medicines Agency (AIFA). AIFA follow a strict timeline and all requests must be made, at the very latest, 60 days prior to the Congress. With this in mind and to help us through this process we have mandated the AIM Group agency who will coordinate the entire application on behalf of all pharmaceutical companies wishing to participate in the Congress in Rome. There will be a small surcharge of invoiced to all companies to guide you through the process and make sure you deliver the requested documents and information on time as part of the official procedure
AIM Group contact details
Mrs. Valentina Disabato / Mrs. Cristina Ghidoli
Tel.: +39 02566011
e-mail : firstname.lastname@example.org
Ali Canbay, Germany
Claus Hellerbrand, Germany
Wing-Kin Syn, United States
Michael Trauner, Austria